FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3035084006> ?p ?o ?g. }

• W3035084006 abstract "Objective: To determine the efficacy and safety of risdiplam (RG7916) in infants with Type 1 spinal muscular atrophy (SMA) treated for 12 months during the confirmatory Part 2 of the FIREFISH study. Background: SMA is a severe, progressive neuromuscular disease caused by reduced levels of survival of motor neuron (SMN) protein due to deletions and/or mutations of the SMN1 gene. A second gene, SMN2, produces only low levels of functional SMN protein. Risdiplam is an orally administered, centrally and peripherally distributed SMN2 pre-mRNA splicing modifier that increases the levels of functional SMN protein. Design/Methods: FIREFISH (NCT02913482) is an ongoing, multicenter, open-label study of risdiplam in infants aged 1–7 months at enrollment with Type 1 SMA and two SMN2 gene copies. FIREFISH Part 1 (n=21) assesses the safety, tolerability, pharmacokinetics and pharmacodynamics of different risdiplam dose levels (plus exploratory efficacy outcomes). In FIREFISH Part 1 there have been no drug-related safety findings leading to withdrawal from the study following ≤30 (median 19) months of treatment (data-cut: 2nd July 2019). The primary objective of confirmatory Part 2 (n=41) is to investigate the efficacy of risdiplam at the dose selected in Part 1. The primary efficacy endpoint is the proportion of infants sitting without support for 5 seconds after 12 months on treatment, as assessed by Item 22 of the Gross Motor Scale of the Bayley Scales of Infant and Toddler Development, third edition (BSID-III). Additional secondary endpoints will also be measured. Results: Here we will report efficacy and safety data from the confirmatory Part 2 of the FIREFISH study in participants who have received treatment with risdiplam for a minimum of 12 months at the dose selected in Part 1. Conclusions: Part 2 of FIREFISH will provide important data on the efficacy and safety of risdiplam in infants with Type 1 SMA. Disclosure: Dr. Servais has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Avexis, Inc., Biogen, Biophytis, Cytokinetics, Dynacure, Roche, Santhera, Sarepta Therapeutics. Dr. Servais has received research support from Avexis, Inc., Biogen, Dynacure, and Roche. Dr. Baranello has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AveXis and Roche. Dr. Masson has nothing to disclose. Dr. Mazurkiewicz-Beldzin has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen and Biomarin. Dr. Rose has nothing to disclose. Dr. Vlodavets has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with PTC therapeutics, Roche, Novartis, Sarepta Therapeutics, Avexus, Jannses, MARLIN Biotech. Dr. Xiong has nothing to disclose. Dr. Zanotelli has nothing to disclose. Dr. El-Khairi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Roche Products Limited. Dr. El-Khairi holds stock and/or stock options in Roche Holding AG. Dr. Fuerst-Recktenwald has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with F. Hoffmann-La Roche Ltd.. Dr. Fuerst-Recktenwald holds stock and/or stock options in F. Hoffmann-La Roche Ltd. which sponsored research in which Dr. Fuerst-Recktenwald was involved as an investigator. Dr. Fuerst-Recktenwald holds stock and/or stock options in F. Hoffmann-La Roche Ltd.. Dr. Gerber has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Hoffmann-La Roche. Dr. Gerber has received compensation for serving on the Board of Directors of Sponsor. Dr. Gerber holds stock and/or stock options in Hoffmann-La Roche which sponsored research in which Dr. Gerber was involved as an investigator. Dr. Gerber holds stock and/or stock options in Hoffmann-La Roche. Dr. Gorni has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with F.Hoffmann-La Roche. Dr. Kletzl has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Hoffmann-La Roche. Dr. Kletzl holds stock and/or stock options in Hoffmann-La Roche which sponsored research in which Dr. Kletzl was involved as an investigator. Dr. Kletzl holds stock and/or stock options in Hoffmann-La Roche. Dr. Kletzl has received research support from Hoffmann-La Roche. Dr. Scalco has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Hoffmann-La Roche. Dr. Scalco holds stock and/or stock options in Hoffmann-La Roche which sponsored research in which Dr. Scalco was involved as an investigator. Dr. Scalco has received research support from Hoffmann-La Roche. Dr. Darras has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AveXis, Biogen, Bristol-Myers Squibb, Cytokinetics, Marathon, PTC Therapeutics, Roche, Santhera, and Sarepta. Dr. Darras has received research support from the National Institutes of Health/National Institute of Neurological Disorders and Stroke, the Slaney Family Fund for SMA, Working on Walking Fund, the SMA Foundation; CureSMA, Ionis Pharmaceuticals, Inc. and Biogen, AveXis, Cytokinetics, Fibrogen, PTC Th." @default.
• W3035084006 created "2020-06-19" @default.
• W3035084006 creator A5002367971 @default.
• W3035084006 creator A5003682249 @default.
• W3035084006 creator A5011213147 @default.
• W3035084006 creator A5012816116 @default.
• W3035084006 creator A5024370512 @default.
• W3035084006 creator A5038576080 @default.
• W3035084006 creator A5041697615 @default.
• W3035084006 creator A5058605651 @default.
• W3035084006 creator A5061093150 @default.
• W3035084006 creator A5066025079 @default.
• W3035084006 creator A5076402259 @default.
• W3035084006 creator A5080170992 @default.
• W3035084006 creator A5081481886 @default.
• W3035084006 creator A5086466823 @default.
• W3035084006 creator A5089502940 @default.
• W3035084006 date "2020-04-14" @default.
• W3035084006 modified "2023-09-25" @default.
• W3035084006 title "FIREFISH Part 2: Efficacy and Safety of Risdiplam (RG7916) in Infants with Type 1 Spinal Muscular Atrophy (SMA) (1302)" @default.
• W3035084006 hasPublicationYear "2020" @default.
• W3035084006 type Work @default.
• W3035084006 sameAs 3035084006 @default.
• W3035084006 citedByCount "0" @default.
• W3035084006 crossrefType "journal-article" @default.
• W3035084006 hasAuthorship W3035084006A5002367971 @default.
• W3035084006 hasAuthorship W3035084006A5003682249 @default.
• W3035084006 hasAuthorship W3035084006A5011213147 @default.
• W3035084006 hasAuthorship W3035084006A5012816116 @default.
• W3035084006 hasAuthorship W3035084006A5024370512 @default.
• W3035084006 hasAuthorship W3035084006A5038576080 @default.
• W3035084006 hasAuthorship W3035084006A5041697615 @default.
• W3035084006 hasAuthorship W3035084006A5058605651 @default.
• W3035084006 hasAuthorship W3035084006A5061093150 @default.
• W3035084006 hasAuthorship W3035084006A5066025079 @default.
• W3035084006 hasAuthorship W3035084006A5076402259 @default.
• W3035084006 hasAuthorship W3035084006A5080170992 @default.
• W3035084006 hasAuthorship W3035084006A5081481886 @default.
• W3035084006 hasAuthorship W3035084006A5086466823 @default.
• W3035084006 hasAuthorship W3035084006A5089502940 @default.
• W3035084006 hasConcept C114614502 @default.
• W3035084006 hasConcept C126322002 @default.
• W3035084006 hasConcept C138496976 @default.
• W3035084006 hasConcept C143998085 @default.
• W3035084006 hasConcept C15744967 @default.
• W3035084006 hasConcept C161921814 @default.
• W3035084006 hasConcept C187212893 @default.
• W3035084006 hasConcept C197934379 @default.
• W3035084006 hasConcept C203092338 @default.
• W3035084006 hasConcept C2778045022 @default.
• W3035084006 hasConcept C2778242525 @default.
• W3035084006 hasConcept C2778375690 @default.
• W3035084006 hasConcept C2778558090 @default.
• W3035084006 hasConcept C2779134260 @default.
• W3035084006 hasConcept C33923547 @default.
• W3035084006 hasConcept C535046627 @default.
• W3035084006 hasConcept C71924100 @default.
• W3035084006 hasConceptScore W3035084006C114614502 @default.
• W3035084006 hasConceptScore W3035084006C126322002 @default.
• W3035084006 hasConceptScore W3035084006C138496976 @default.
• W3035084006 hasConceptScore W3035084006C143998085 @default.
• W3035084006 hasConceptScore W3035084006C15744967 @default.
• W3035084006 hasConceptScore W3035084006C161921814 @default.
• W3035084006 hasConceptScore W3035084006C187212893 @default.
• W3035084006 hasConceptScore W3035084006C197934379 @default.
• W3035084006 hasConceptScore W3035084006C203092338 @default.
• W3035084006 hasConceptScore W3035084006C2778045022 @default.
• W3035084006 hasConceptScore W3035084006C2778242525 @default.
• W3035084006 hasConceptScore W3035084006C2778375690 @default.
• W3035084006 hasConceptScore W3035084006C2778558090 @default.
• W3035084006 hasConceptScore W3035084006C2779134260 @default.
• W3035084006 hasConceptScore W3035084006C33923547 @default.
• W3035084006 hasConceptScore W3035084006C535046627 @default.
• W3035084006 hasConceptScore W3035084006C71924100 @default.
• W3035084006 hasLocation W30350840061 @default.
• W3035084006 hasOpenAccess W3035084006 @default.
• W3035084006 hasPrimaryLocation W30350840061 @default.
• W3035084006 hasRelatedWork W2802602953 @default.
• W3035084006 hasRelatedWork W2806618339 @default.
• W3035084006 hasRelatedWork W2953906311 @default.
• W3035084006 hasRelatedWork W2986571496 @default.
• W3035084006 hasRelatedWork W2989973956 @default.
• W3035084006 hasRelatedWork W3049486141 @default.
• W3035084006 hasRelatedWork W3094135316 @default.
• W3035084006 hasRelatedWork W3114248459 @default.
• W3035084006 hasRelatedWork W3156936539 @default.
• W3035084006 hasRelatedWork W3164733548 @default.
• W3035084006 hasRelatedWork W3184811931 @default.
• W3035084006 hasRelatedWork W3185891165 @default.
• W3035084006 hasRelatedWork W3185915088 @default.
• W3035084006 hasRelatedWork W3193837412 @default.
• W3035084006 hasRelatedWork W3198099375 @default.
• W3035084006 hasRelatedWork W3198530510 @default.
• W3035084006 hasRelatedWork W3200253992 @default.
• W3035084006 hasRelatedWork W3204778907 @default.
• W3035084006 hasRelatedWork W3214525382 @default.
• W3035084006 hasRelatedWork W3087140353 @default.
• W3035084006 hasVolume "94" @default.
• W3035084006 isParatext "false" @default.
• W3035084006 isRetracted "false" @default.

• next